Recherche - Archive ouverte HAL Accéder directement au contenu

Filtrer vos résultats

8 Résultats
authFullName_s : T. Lecomte

PO-0702: Phase I trial evaluating panitumumab in combination with chemoradiotherapy for anal cancers

V. Vendrely , C. Lemanski , E. Le Prise , E. Maillard , X. Mirabel et al.
ESTRO 36, May 2017, Vienne, Austria. , Radiotherapy and Oncology, 123 (Supplement 1), pp.S367 - S368, 2017, ESTRO 36, May 5-9, 2017, Vienna, Austria. ⟨10.1016/S0167-8140(17)31139-8⟩
Poster de conférence hal-01685153v1
Image document

Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study

Côme Lepage , J-M. Phelip , Astrid Lièvre , Karine Le Malicot , L Dahan et al.
European Journal of Cancer, 2022, 175, pp.31-40. ⟨10.1016/j.ejca.2022.07.033⟩
Article dans une revue hal-03810530v1

Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20

T. Aparicio , O. Bouché , E. Francois , E. Maillard , S. Kirscher et al.
41st Congress of the European-Society-for-Medical-Oncology (ESMO), Oct 2016, Copenhague, Denmark. ⟨10.1093/annonc/mdw370.131⟩
Communication dans un congrès hal-01524852v1

PFOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial

J-B. Bachet , O. Lucidarme , C.B. Levache , E. Maillard , J.L. Raoul et al.
the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. pp.505P, ⟨10.1093/annonc/mdx393.031⟩
Communication dans un congrès hal-01632415v1

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results

T. Aparicio , O. Bouché , J. Taieb , E. Maillard , S. Kirscher et al.
Annals of Oncology, 2018, 29 (1), pp.133-138. ⟨10.1093/annonc/mdx529⟩
Article dans une revue hal-01699429v1

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer

T. Aparicio , O. Bouché , E. Francois , F. Retornaz , E. Barbier et al.
European Journal of Cancer, 2018, 97, pp.16-24. ⟨10.1016/j.ejca.2018.03.030⟩
Article dans une revue hal-02012206v1

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial

J.B. Bachet , O. Lucidarme , C.B. Levache , E. Barbier , J.L. Raoul et al.
European Journal of Cancer, 2018, 104, pp.108-116. ⟨10.1016/j.ejca.2018.09.006⟩
Article dans une revue hal-01960176v1

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort

T. Walter , T Tougeron , Emmanuel Baudin , K. Le Malicot , T. Lecomte et al.
European Journal of Cancer, 2017, 79, pp.158 - 165. ⟨10.1016/j.ejca.2017.04.009⟩
Article dans une revue hal-01609152v1